• Главная
  • NEW DAY MEDICINE
  • 3 (89) 2026
  • 53 -3 (89) 2026 - Yuldasheva D.Kh., Abidova I.Kh. - ASSESSMENT OF CHANGES IN INTESTINAL MICROBIOCENOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE USING CLINICAL AND LABORATORY MARKERS

53 -3 (89) 2026 - Yuldasheva D.Kh., Abidova I.Kh. - ASSESSMENT OF CHANGES IN INTESTINAL MICROBIOCENOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE USING CLINICAL AND LABORATORY MARKERS

ASSESSMENT OF CHANGES IN INTESTINAL MICROBIOCENOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE USING CLINICAL AND LABORATORY MARKERS

Yuldasheva D.Kh. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Abidova I.Kh. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

This study investigated the state of intestinal microbiocenosis in patients with non-alcoholic fatty liver disease (NAFLD), assessed using clinical and laboratory parameters. The study included 108 patients with NAFLD and 60 healthy individuals in the control group. Clinical and laboratory findings demonstrated that patients with NAFLD had significantly higher levels of liver cytolysis enzymes (ALT and AST), as well as increased glucose and lipid profile indicators compared to the control group, indicating hepatocellular damage and chronic inflammatory processes. Assessment of intestinal microbiocenosis revealed a significant decrease in bifidobacteria and lactobacilli, along with an increase in opportunistic microflora, indicating the presence of intestinal dysbiosis in NAFLD patients. These changes are associated with elevated inflammatory activity and liver cell damage.

Keywords: non-alcoholic fatty liver disease, intestinal microbiocenosis, dysbiosis, ALT, bifidobacteria, lactobacilli.

First page

334

Last page

338

For citation:Yuldasheva D.Kh., Abidova I.Kh. - ASSESSMENT OF CHANGES IN INTESTINAL MICROBIOCENOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE USING CLINICAL AND LABORATORY MARKERS//New Day in Medicine 3(89)2026 334-338 https://newdayworldmedicine.com/en/new_day_medicine/3-89-2026

List of References

  1. Ибрагимов АР. Жигар стеатози ва метаболик синдромнинг клиник хусусиятлари. Ўзбекистон тиббиёт журнали. 2021;(4):32–37.
  2. Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Ann Hepatol. 2018;17(1):1–8. doi:10.5604/01.3001.0010.7534.
  3. Tilg H, Moschen AR. Gut–liver axis in non-alcoholic fatty liver disease. J Hepatol. 2020;73(2):328–339. doi:10.1016/j.jhep.2020.04.003.
  4. Boursier J, Diehl AM. Implication of gut microbiota in nonalcoholic fatty liver disease. Hepatology. 2016;63(3):764–775. doi:10.1002/hep.28356.
  5. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862–873. doi:10.1016/j.jhep.2017.06.003.
  6. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction–associated fatty liver disease. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039.

    file

    download